Despite recent advances in the systemic treatment of gastroesophageal cancers, prognosis
remains poor. Comprehensive molecular analyses have characterized the genomic …

Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and
is mediated by mechanisms including compensatory ligand upregulation and de novo gene …

Abstract Purpose: Anti-EGF receptor (EGFR) antibodies and small-molecule tyrosine kinase
inhibitors have shown activity in epithelial tumors; however, agents that work by blocking the …

Background Esophagogastric adenocarcinoma (EGA) currently represents a main cause of
cancer related death. Despite an intensified treatment for locally advanced or metastatic …

HER2 expression remains an important biomarker to guide the addition of the monoclonal
antibody trastuzumab to first-line systemic chemotherapy in unresectable, metastatic …

Background Erlotinib and gefitinib are weak base drugs whose absorption and clinical
efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton …

Background Trastuzumab stimulates HER2-specific T cell responses and increases tumour
PD-L1 expression, and anti-PD-1 antibody can help enhance T cell-specific immunity of …

Esophageal cancer (EC) is among the most frequent and deadly cancers around the world.
While esophageal adenocarcinoma (EAC) has one of the fastest-growing incidences …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It
was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are …